## Paolo Fusar-Poli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8896038/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry,the, 2020, 7, 611-627.	7.4	1,799
2	The Psychosis High-Risk State. JAMA Psychiatry, 2013, 70, 107.	11.0	1,222
3	Predicting Psychosis. Archives of General Psychiatry, 2012, 69, 220.	12.3	1,214
4	Age at onset of mental disorders worldwide: large-scale meta-analysis ofÂ192 epidemiological studies. Molecular Psychiatry, 2022, 27, 281-295.	7.9	967
5	Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. Journal of Psychiatry and Neuroscience, 2009, 34, 418-32.	2.4	959
6	Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology. Neuropsychopharmacology, 2010, 35, 764-774.	5.4	595
7	Cognitive Functioning in Prodromal Psychosis. Archives of General Psychiatry, 2012, 69, 562-71.	12.3	567
8	Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophrenia Bulletin, 2015, 41, 892-899.	4.3	505
9	Comorbid Depressive and Anxiety Disorders in 509 Individuals With an At-Risk Mental State: Impact on Psychopathology and Transition to Psychosis. Schizophrenia Bulletin, 2014, 40, 120-131.	4.3	499
10	Impact of coronavirus syndromes on physical and mental health of health care workers: Systematic review and meta-analysis. Journal of Affective Disorders, 2020, 275, 48-57.	4.1	438
11	Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neuroscience and Biobehavioral Reviews, 2013, 37, 1680-1691.	6.1	434
12	Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. Archives of General Psychiatry, 2009, 66, 95.	12.3	412
13	Altering the course of schizophrenia: progress and perspectives. Nature Reviews Drug Discovery, 2016, 15, 485-515.	46.4	410
14	Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 2011, 25, 121-130.	4.0	406
15	Cannabis and anxiety: a critical review of the evidence. Human Psychopharmacology, 2009, 24, 515-523.	1.5	398
16	What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry, 2018, 17, 49-66.	10.4	387
17	The impact of COVID-19 lockdown on child and adolescent mental health: systematic review. European Child and Adolescent Psychiatry, 2023, 32, 1151-1177.	4.7	364
18	Improving outcomes of firstâ€episode psychosis: an overview. World Psychiatry, 2017, 16, 251-265.	10.4	363

#	Article	IF	CITATIONS
19	Publication and other reporting biases in cognitive sciences: detection, prevalence, and prevention. Trends in Cognitive Sciences, 2014, 18, 235-241.	7.8	361
20	Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk. JAMA Psychiatry, 2016, 73, 113.	11.0	354
21	Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings. PLoS ONE, 2013, 8, e55821.	2.5	334
22	Neuroanatomy of vulnerability to psychosis: A voxel-based meta-analysis. Neuroscience and Biobehavioral Reviews, 2011, 35, 1175-1185.	6.1	319
23	Ten simple rules for conducting umbrella reviews. Evidence-Based Mental Health, 2018, 21, 95-100.	4.5	317
24	Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neuroscience and Biobehavioral Reviews, 2012, 36, 2325-2333.	6.1	311
25	Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2010, 34, 1207-1222.	6.1	287
26	Prevention of Psychosis. JAMA Psychiatry, 2020, 77, 755.	11.0	287
27	Anisotropic Kernels for Coordinate-Based Meta-Analyses of Neuroimaging Studies. Frontiers in Psychiatry, 2014, 5, 13.	2.6	286
28	Ventral Striatal Activation During Reward Processing in Psychosis. JAMA Psychiatry, 2015, 72, 1243.	11.0	282
29	Neurofunctional correlates of vulnerability to psychosis: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2007, 31, 465-484.	6.1	276
30	Neuroanatomical Maps of Psychosis Onset: Voxel-wise Meta-Analysis of Antipsychotic-Naive VBM Studies. Schizophrenia Bulletin, 2012, 38, 1297-1307.	4.3	254
31	Effects of Cannabis on Neurocognitive Functioning: Recent Advances, Neurodevelopmental Influences, and Sex Differences. Neuropsychology Review, 2013, 23, 117-137.	4.9	252
32	Deconstructing Vulnerability for Psychosis: Meta-Analysis of Environmental Risk Factors for Psychosis in Subjects at Ultra High-Risk. European Psychiatry, 2017, 40, 65-75.	0.2	241
33	Abnormal Frontostriatal Interactions in People With Prodromal Signs of Psychosis. Archives of General Psychiatry, 2010, 67, 683.	12.3	235
34	Modulation of Mediotemporal and Ventrostriatal Function in Humans by Δ9-Tetrahydrocannabinol. Archives of General Psychiatry, 2009, 66, 442.	12.3	226
35	Disorder, not just state of risk: Meta-analysis of functioning and quality of life in people at high risk of psychosis. British Journal of Psychiatry, 2015, 207, 198-206.	2.8	226
36	Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies. Schizophrenia Bulletin, 2013, 39, 33-42.	4.3	224

#	Article	IF	CITATIONS
37	Transdiagnostic psychiatry: a systematic review. World Psychiatry, 2019, 18, 192-207.	10.4	218
38	At risk or not at risk? A metaâ€analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry, 2015, 14, 322-332.	10.4	209
39	Development and Validation of a Clinically Based Risk Calculator for the Transdiagnostic Prediction of Psychosis. JAMA Psychiatry, 2017, 74, 493.	11.0	206
40	Prevalence and Psychosocial Correlates of Mental Health Outcomes Among Chinese College Students During the Coronavirus Disease (COVID-19) Pandemic. Frontiers in Psychiatry, 2020, 11, 803.	2.6	206
41	Dopaminergic basis of salience dysregulation in psychosis. Trends in Neurosciences, 2014, 37, 85-94.	8.6	204
42	Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis. Lancet Psychiatry,the, 2021, 8, 797-812.	7.4	202
43	White Matter Alterations in Early Stages of Schizophrenia: A Systematic Review of Diffusion Tensor Imaging Studies. Journal of Neuroimaging, 2014, 24, 101-110.	2.0	201
44	Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Molecular Psychiatry, 2011, 16, 67-75.	7.9	198
45	Striatal Dopamine Transporter Alterations in ADHD: Pathophysiology or Adaptation to Psychostimulants? A Meta-Analysis. American Journal of Psychiatry, 2012, 169, 264-272.	7.2	198
46	Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing. Archives of General Psychiatry, 2012, 69, 27.	12.3	193
47	The Effects of Antipsychotics on the Brain: What Have We Learnt from Structural Imaging of Schizophrenia? – A Systematic Review. Current Pharmaceutical Design, 2009, 15, 2535-2549.	1.9	191
48	Antipsychotics' effects on blood levels of cytokines in schizophrenia: A meta-analysis. Schizophrenia Research, 2013, 151, 43-47.	2.0	190
49	Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in firstâ€episode psychosis. Human Brain Mapping, 2009, 30, 4129-4137.	3.6	189
50	Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine, 2010, 40, 383-398.	4.5	189
51	Laterality effect on emotional faces processing: ALE meta-analysis of evidence. Neuroscience Letters, 2009, 452, 262-267.	2.1	185
52	The Dark Side of the Moon: Meta-analytical Impact of Recruitment Strategies on Risk Enrichment in the Clinical High Risk State for Psychosis. Schizophrenia Bulletin, 2016, 42, 732-743.	4.3	183
53	Lack of evidence to favor specific preventive interventions in psychosis: a network metaâ€analysis. World Psychiatry, 2018, 17, 196-209.	10.4	183
54	Preventive psychiatry: a blueprint for improving the mental health of young people. World Psychiatry, 2021, 20, 200-221.	10.4	183

#	Article	IF	CITATIONS
55	Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis. Lancet Psychiatry,the, 2020, 7, 399-410.	7.4	182
56	Neural Basis of Δ-9-Tetrahydrocannabinol and Cannabidiol: Effects During Response Inhibition. Biological Psychiatry, 2008, 64, 966-973.	1.3	179
57	Co-occurring mental and substance abuse disorders: A review on the potential predictors and clinical outcomes. Psychiatry Research, 2011, 186, 159-164.	3.3	177
58	Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychological Medicine, 2014, 44, 17-24.	4.5	174
59	Outreach and support in South London (OASIS), 2001–2011: Ten years of early diagnosis and treatment for young individuals at high clinical risk for psychosis. European Psychiatry, 2013, 28, 315-326.	0.2	172
60	The Clinical High-Risk State for Psychosis (CHR-P), Version II. Schizophrenia Bulletin, 2017, 43, 44-47.	4.3	169
61	Environmental risk factors and biomarkers for autism spectrum disorder: an umbrella review of the evidence. Lancet Psychiatry,the, 2019, 6, 590-600.	7.4	169
62	Safety of 80 antidepressants, antipsychotics, antiâ€attentionâ€deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic metaâ€review of 78 adverse effects. World Psychiatry, 2020, 19, 214-232.	10.4	167
63	At Risk for Schizophrenic or Affective Psychoses? A Meta-Analysis of DSM/ICD Diagnostic Outcomes in Individuals at High Clinical Risk. Schizophrenia Bulletin, 2013, 39, 923-932.	4.3	165
64	Neurophysiological effects of acute oxytocin administration: systematic review and meta-analysis of placebo-controlled imaging studies. Journal of Psychiatry and Neuroscience, 2015, 40, E1-E22.	2.4	159
65	Basic Symptoms and the Prediction of First-Episode Psychosis. Current Pharmaceutical Design, 2012, 18, 351-357.	1.9	152
66	Diagnostic Stability of ICD/DSM First Episode Psychosis Diagnoses: Meta-analysis. Schizophrenia Bulletin, 2016, 42, 1395-1406.	4.3	151
67	The Science of Prognosis in Psychiatry. JAMA Psychiatry, 2018, 75, 1289.	11.0	151
68	Probability of Transition to Psychosis in Individuals at Clinical High Risk. JAMA Psychiatry, 2021, 78, 970.	11.0	148
69	Brain Structural Abnormalities at the Onset of Schizophrenia and Bipolar Disorder: A Meta-analysis of Controlled Magnetic Resonance Imaging Studies. Current Pharmaceutical Design, 2012, 18, 486-494.	1.9	144
70	Prevalence of self-reported childhood abuse in psychosis: A meta-analysis of retrospective studies. Psychiatry Research, 2013, 210, 8-15.	3.3	144
71	Association of Antidepressant Use With Adverse Health Outcomes. JAMA Psychiatry, 2019, 76, 1241.	11.0	143
72	Neural correlates of executive function and working memory in the †at-risk mental state'. British Journal of Psychiatry, 2009, 194, 25-33.	2.8	141

#	Article	IF	CITATIONS
73	Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends in Pharmacological Sciences, 2008, 29, 91-98.	8.7	138
74	Prognosis of Brief Psychotic Episodes. JAMA Psychiatry, 2016, 73, 211.	11.0	137
75	Modulation of effective connectivity during emotional processing by Δ9-tetrahydrocannabinol and cannabidiol. International Journal of Neuropsychopharmacology, 2010, 13, 421.	2.1	134
76	A largeâ€scale metaâ€analytic atlas of mental health problems prevalence during the COVIDâ€19 early pandemic. Journal of Medical Virology, 2022, 94, 1935-1949.	5.0	134
77	What is good mental health? A scoping review. European Neuropsychopharmacology, 2020, 31, 33-46.	0.7	131
78	Risk and protective factors for mental disorders beyond genetics: an evidenceâ€based atlas. World Psychiatry, 2021, 20, 417-436.	10.4	127
79	Modulation of Auditory and Visual Processing by Delta-9-Tetrahydrocannabinol and Cannabidiol: an fMRI Study. Neuropsychopharmacology, 2011, 36, 1340-1348.	5.4	126
80	Oligodendroglial Alterations and the Role of Microglia in White Matter Injury: Relevance to Schizophrenia. Developmental Neuroscience, 2013, 35, 102-129.	2.0	122
81	Transition to Psychosis Associated With Prefrontal and Subcortical Dysfunction in Ultra High-Risk Individuals. Schizophrenia Bulletin, 2012, 38, 1268-1276.	4.3	120
82	Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. Journal of Affective Disorders, 2016, 203, 101-110.	4.1	120
83	Reduced mismatch negativity predates the onset of psychosis. Schizophrenia Research, 2012, 134, 42-48.	2.0	119
84	Attenuated Psychosis Syndrome: Ready for DSM-5.1?. Annual Review of Clinical Psychology, 2014, 10, 155-192.	12.3	119
85	Peripheral oxytocin and vasopressin: Biomarkers of psychiatric disorders? A comprehensive systematic review and preliminary meta-analysis. Psychiatry Research, 2016, 241, 207-220.	3.3	119
86	BDNF Val66Met polymorphism and hippocampal volume in neuropsychiatric disorders: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2015, 55, 107-118.	6.1	118
87	Risk factors for posttraumatic stress disorder: An umbrella review of systematic reviews and meta-analyses. Neuroscience and Biobehavioral Reviews, 2019, 107, 154-165.	6.1	115
88	Thalamic Glutamate Levels as a Predictor of Cortical Response During Executive Functioning in Subjects at High Risk for Psychosis. Archives of General Psychiatry, 2011, 68, 881.	12.3	114
89	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. Psychiatry Research, 2013, 209, 266-272.	3.3	114
90	Mapping vulnerability to bipolar disorder: a systematic review and meta-analysis of neuroimaging studies. Journal of Psychiatry and Neuroscience, 2012, 37, 170-184.	2.4	112

Paolo Fusar-Poli

#	Article	IF	CITATIONS
91	Why are help-seeking subjects at ultra-high risk for psychosis help-seeking?. Psychiatry Research, 2015, 228, 808-815.	3.3	111
92	Deconstructing Pretest Risk Enrichment to Optimize Prediction of Psychosis in Individuals at Clinical High Risk. JAMA Psychiatry, 2016, 73, 1260.	11.0	111
93	Potential Reporting Bias in fMRI Studies of the Brain. PLoS ONE, 2013, 8, e70104.	2.5	110
94	Eicosapentaenoic Acid Interventions in Schizophrenia. Journal of Clinical Psychopharmacology, 2012, 32, 179-185.	1.4	109
95	Potential Reporting Bias in Neuroimaging Studies of Sex Differences. Scientific Reports, 2018, 8, 6082.	3.3	109
96	Integrated Mental Health Services for the Developmental Period (0 to 25 Years): A Critical Review of the Evidence. Frontiers in Psychiatry, 2019, 10, 355.	2.6	109
97	Disparities in cancer screening in people with mental illness across the world versus the general population: prevalence and comparative meta-analysis including 4â€^717â€^839 people. Lancet Psychiatry,the, 2020, 7, 52-63.	7.4	109
98	Diagnostic and Prognostic Significance of Brief Limited Intermittent Psychotic Symptoms (BLIPS) in Individuals at Ultra High Risk. Schizophrenia Bulletin, 2017, 43, 48-56.	4.3	106
99	Striatal Presynaptic Dopamine in Schizophrenia, Part I: Meta-Analysis of Dopamine Active Transporter (DAT) Density. Schizophrenia Bulletin, 2013, 39, 22-32.	4.3	104
100	Long-term validity of the At Risk Mental State (ARMS) for predicting psychotic and non-psychotic mental disorders. European Psychiatry, 2017, 42, 49-54.	0.2	104
101	What Causes the Onset of Psychosis in Individuals at Clinical High Risk? A Meta-analysis of Risk and Protective Factors. Schizophrenia Bulletin, 2020, 46, 110-120.	4.3	103
102	Environmental risk factors, protective factors, and peripheral biomarkers for ADHD: an umbrella review. Lancet Psychiatry,the, 2020, 7, 955-970.	7.4	103
103	Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders. Translational Psychiatry, 2020, 10, 152.	4.8	102
104	Implementing Precision Psychiatry: A Systematic Review of Individualized Prediction Models for Clinical Practice. Schizophrenia Bulletin, 2021, 47, 284-297.	4.3	101
105	Can We Reduce the Duration of Untreated Psychosis? A Systematic Review and Meta-Analysis of Controlled Interventional Studies. Schizophrenia Bulletin, 2018, 44, 1362-1372.	4.3	100
106	The Phenomenology and Neurobiology of Delusion Formation During Psychosis Onset: Jaspers, Truman Symptoms, and Aberrant Salience. Schizophrenia Bulletin, 2013, 39, 278-286.	4.3	99
107	Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation. Schizophrenia Bulletin, 2017, 43, sbw098.	4.3	98
108	Tracking cerebral white matter changes across the lifespan: insights from diffusion tensor imaging studies. Journal of Neural Transmission, 2013, 120, 1369-1395.	2.8	97

#	Article	IF	CITATIONS
109	Towards a Standard Psychometric Diagnostic Interview for Subjects at Ultra High Risk of Psychosis: CAARMS versus SIPS. Psychiatry Journal, 2016, 2016, 1-11.	1.5	97
110	Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2021, 78, 859.	11.0	96
111	Negative psychotic symptoms and impaired role functioning predict transition outcomes in the at-risk mental state: a latent class cluster analysis study. Psychological Medicine, 2013, 43, 2311-2325.	4.5	95
112	Annual Research Review: Prevention of psychosis in adolescents – systematic review and metaâ€analysis of advances in detection, prognosis and intervention. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 657-673.	5.2	95
113	Brain Connectivity Abnormalities Predating the Onset of Psychosis. JAMA Psychiatry, 2013, 70, 903.	11.0	94
114	Multimodal voxel-based meta-analysis of structural and functional magnetic resonance imaging studies in those at elevated genetic risk of developing schizophrenia. Psychiatry Research - Neuroimaging, 2014, 221, 69-77.	1.8	94
115	Social dysfunction predicts two years clinical outcome in people at ultra high risk for psychosis. Journal of Psychiatric Research, 2010, 44, 294-301.	3.1	92
116	Affective temperamental profiles are associated with white matter hyperintensity and suicidal risk in patients with mood disorders. Journal of Affective Disorders, 2011, 129, 47-55.	4.1	90
117	Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: Longitudinal VBM-fMRI study. Journal of Psychiatric Research, 2011, 45, 190-198.	3.1	89
118	Is cannabis neurotoxic for the healthy brain? A metaâ€analytical review of structural brain alterations in nonâ€psychotic users. Psychiatry and Clinical Neurosciences, 2013, 67, 483-492.	1.8	88
119	Efficacy and Acceptability of Interventions for Attenuated Positive Psychotic Symptoms in Individuals at Clinical High Risk of Psychosis: A Network Meta-Analysis. Frontiers in Psychiatry, 2018, 9, 187.	2.6	87
120	Psychopathological symptoms in child and adolescent migraine and tension-type headache: A meta-analysis. Cephalalgia, 2013, 33, 112-122.	3.9	86
121	Whither the Attenuated Psychosis Syndrome?. Schizophrenia Bulletin, 2012, 38, 1130-1134.	4.3	85
122	Can antidepressants prevent psychosis?. Lancet, The, 2007, 370, 1746-1748.	13.7	84
123	Efficacy and safety of second-generation long-acting injections in schizophrenia. International Clinical Psychopharmacology, 2013, 28, 57-66.	1.7	83
124	Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: A voxelwise meta-analytical comparison. World Journal of Biological Psychiatry, 2014, 15, 219-228.	2.6	83
125	Cannabis use and transition to psychosis in people at ultra-high risk. Psychological Medicine, 2014, 44, 2503-2512.	4.5	83
126	Lithium Exposure During Pregnancy and the Postpartum Period: A Systematic Review and Meta-Analysis of Safety and Efficacy Outcomes. American Journal of Psychiatry, 2020, 177, 76-92.	7.2	83

#	Article	IF	CITATIONS
127	Clinical Validity of <i>DSM-5</i> Attenuated Psychosis Syndrome. JAMA Psychiatry, 2020, 77, 311.	11.0	82
128	Peripheral levels of C-reactive protein, tumor necrosis factor-α, interleukin-6, and interleukin-1β across the mood spectrum in bipolar disorder: A meta-analysis of mean differences and variability. Brain, Behavior, and Immunity, 2021, 97, 193-203.	4.1	80
129	Serotonin transporter in Parkinson's disease: A metaâ€analysis of positron emission tomography studies. Annals of Neurology, 2017, 81, 171-180.	5.3	77
130	Efficacy and acceptability of pharmacological, psychosocial, and brain stimulation interventions in children and adolescents with mental disorders: an umbrella review. World Psychiatry, 2021, 20, 244-275.	10.4	76
131	Cannabidiol as a potential treatment for psychosis. European Neuropsychopharmacology, 2014, 24, 51-64.	0.7	75
132	Ten Years of "Extended―Life: Quality of Life Among Heart Transplantation Survivors. Transplantation, 2004, 78, 257-263.	1.0	74
133	Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk and the Prediction of Psychosis: Second Replication in an Independent National Health Service Trust. Schizophrenia Bulletin, 2019, 45, 562-570.	4.3	74
134	Association of Structural Magnetic Resonance Imaging Measures With Psychosis Onset in Individuals at Clinical High Risk for Developing Psychosis. JAMA Psychiatry, 2021, 78, 753.	11.0	74
135	Preventive Treatments for Psychosis: Umbrella Review (Just the Evidence). Frontiers in Psychiatry, 2019, 10, 764.	2.6	72
136	Altered Prefrontal and Hippocampal Function During Verbal Encoding and Recognition in People With Prodromal Symptoms of Psychosis. Schizophrenia Bulletin, 2011, 37, 746-756.	4.3	71
137	Abnormal Relationship Between Medial Temporal Lobe and Subcortical Dopamine Function in People With an Ultra High Risk for Psychosis. Schizophrenia Bulletin, 2012, 38, 1040-1049.	4.3	71
138	Mapping prodromal psychosis: A critical review of neuroimaging studies. European Psychiatry, 2012, 27, 181-191.	0.2	70
139	Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. World Journal of Biological Psychiatry, 2013, 14, 412-431.	2.6	69
140	Speed of Psychosis Progression in People at Ultra-High Clinical Risk. JAMA Psychiatry, 2015, 72, 622.	11.0	69
141	The lived experience of psychosis: a bottomâ€up review coâ€written by experts by experience and academics. World Psychiatry, 2022, 21, 168-188.	10.4	67
142	Duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. British Journal of Psychiatry, 2015, 207, 130-134.	2.8	65
143	Spatial working memory in individuals at high risk for psychosis: Longitudinal fMRI study. Schizophrenia Research, 2010, 123, 45-52.	2.0	64
144	Interpersonal sensitivity in the at-risk mental state for psychosis. Psychological Medicine, 2012, 42, 1835-1845.	4.5	63

#	Article	IF	CITATIONS
145	Antidepressant, antipsychotic and psychological interventions in subjects at high clinical risk for psychosis: OASIS 6-year naturalistic study. Psychological Medicine, 2015, 45, 1327-1339.	4.5	60
146	Altered Medial Temporal Activation Related to Local Glutamate Levels in Subjects with Prodromal Signs of Psychosis. Biological Psychiatry, 2011, 69, 97-99.	1.3	59
147	Functional Outcome in People at High Risk for Psychosis Predicted by Thalamic Glutamate Levels and Prefronto-Striatal Activation. Schizophrenia Bulletin, 2015, 41, 429-439.	4.3	59
148	Antipsychotic use and risk of lifeâ€ŧhreatening medical events: umbrella review of observational studies. Acta Psychiatrica Scandinavica, 2019, 140, 227-243.	4.5	59
149	Predicting the onset of psychosis in patients at clinical high risk: practical guide to probabilistic prognostic reasoning. Evidence-Based Mental Health, 2016, 19, 10-15.	4.5	58
150	Worldwide implementation of clinical services for the prevention of psychosis: The IEPA early intervention in mental health survey. Microbial Biotechnology, 2020, 14, 741-750.	1.7	58
151	Improving the Detection of Individuals at Clinical Risk for Psychosis in the Community, Primary and Secondary Care: An Integrated Evidence-Based Approach. Frontiers in Psychiatry, 2019, 10, 774.	2.6	57
152	Risk factors for eating disorders: an umbrella review of published meta-analyses. Revista Brasileira De Psiquiatria, 2021, 43, 314-323.	1.7	57
153	Approaching a network connectivity-driven classification of the psychosis continuum: a selective review and suggestions for future research. Frontiers in Human Neuroscience, 2014, 8, 1047.	2.0	56
154	Meta-analysis of Voxel-Based Neuroimaging Studies using Seed-based d Mapping with Permutation of Subject Images (SDM-PSI). Journal of Visualized Experiments, 2019, , .	0.3	56
155	Towards Precision Medicine in Psychosis: Benefits and Challenges of Multimodal Multicenter Studies—PSYSCAN: Translating Neuroimaging Findings From Research into Clinical Practice. Schizophrenia Bulletin, 2020, 46, 432-441.	4.3	56
156	Universal and selective interventions to promote good mental health in young people: Systematic review and meta-analysis. European Neuropsychopharmacology, 2020, 41, 28-39.	0.7	56
157	Should attenuated psychosis syndrome be included in DSM-5?. Lancet, The, 2012, 379, 591-592.	13.7	55
158	Lost in transition: setting the psychosis threshold in prodromal research. Acta Psychiatrica Scandinavica, 2013, 127, 248-252.	4.5	55
159	Immigration, Social Environment and Onset of Psychotic Disorders. Current Pharmaceutical Design, 2012, 18, 518-526.	1.9	54
160	Using neuroimaging to help predict the onset of psychosis. NeuroImage, 2017, 145, 209-217.	4.2	54
161	Determinants of Quality of Life in Marfan Syndrome. Psychosomatics, 2008, 49, 243-248.	2.5	53
162	Prefrontal Function at Presentation Directly Related to Clinical Outcome in People at Ultrahigh Risk of Psychosis. Schizophrenia Bulletin, 2011, 37, 189-198.	4.3	53

#	Article	IF	CITATIONS
163	Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis. Therapeutic Advances in Psychopharmacology, 2013, 3, 89-99.	2.7	53
164	Depression and Quality of Life in Patients Living 10 to 18 Years Beyond Heart Transplantation. Journal of Heart and Lung Transplantation, 2005, 24, 2269-2278.	0.6	52
165	Neuroimaging and electrophysiological studies of the effects of acute tryptophan depletion: a systematic review of the literature. Psychopharmacology, 2006, 188, 131-143.	3.1	52
166	Duration of untreated prodromal symptoms and 12-month functional outcome of individuals at risk of psychosis. British Journal of Psychiatry, 2009, 194, 181-182.	2.8	52
167	Gray matter alterations related to P300 abnormalities in subjects at high risk for psychosis: Longitudinal MRI-EEG study. NeuroImage, 2011, 55, 320-328.	4.2	52
168	Incidence, prevalence, and global burden of autism spectrum disorder from 1990 to 2019 across 204 countries. Molecular Psychiatry, 2022, 27, 4172-4180.	7.9	52
169	Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis. Journal of Psychiatry and Neuroscience, 2012, 37, 106-112.	2.4	51
170	From the Prodrome to Chronic Schizophrenia: The Neurobiology Underlying Psychotic Symptoms and Cognitive Impairments. Current Pharmaceutical Design, 2012, 18, 459-465.	1.9	51
171	Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ <sup>9</sup> -tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychological Medicine, 2013, 43, 1255-1267.	4.5	51
172	Imaging the Neural Effects of Cannabinoids: Current Status and Future Opportunities for Psychopharmacology. Current Pharmaceutical Design, 2009, 15, 2603-2614.	1.9	50
173	Insular volume abnormalities associated with different transition probabilities to psychosis. Psychological Medicine, 2012, 42, 1613-1625.	4.5	50
174	Evidence of reporting biases in voxel-based morphometry (VBM) studies of psychiatric and neurological disorders. Human Brain Mapping, 2014, 35, 3052-3065.	3.6	50
175	Severe mental illness and European COVID-19 vaccination strategies. Lancet Psychiatry,the, 2021, 8, 356-359.	7.4	50
176	Disparities in Screening and Treatment of Cardiovascular Diseases in Patients With Mental Disorders Across the World: Systematic Review and Meta-Analysis of 47 Observational Studies. American Journal of Psychiatry, 2021, 178, 793-803.	7.2	50
177	What Is an Attenuated Psychotic Symptom? On the Importance of the Context. Schizophrenia Bulletin, 2017, 43, sbw182.	4.3	49
178	Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges. Molecular Psychiatry, 2022, 27, 2700-2708.	7.9	49
179	Effects of acute antipsychotic treatment on brain activation in first episode psychosis: An fMRI study. European Neuropsychopharmacology, 2007, 17, 492-500.	0.7	48
180	Neurofunctional maps of the â€~maternal brain' and the effects of oxytocin: A multimodal voxelâ€based metaâ€analysis. Psychiatry and Clinical Neurosciences, 2014, 68, 733-751.	1.8	48

#	Article	IF	CITATIONS
181	Extending the Benefits of Indicated Prevention to Improve Outcomes of First-Episode Psychosis. JAMA Psychiatry, 2017, 74, 667.	11.0	48
182	A general approach for combining voxel-based meta-analyses conducted in different neuroimaging modalities. Current Medicinal Chemistry, 2013, 20, 462-6.	2.4	48
183	Altered activation and connectivity in a hippocampal–basal ganglia–midbrain circuit during salience processing in subjects at ultra high risk for psychosis. Translational Psychiatry, 2017, 7, e1245-e1245.	4.8	47
184	Establishing a clinical service to prevent psychosis: What, how and when? Systematic review. Translational Psychiatry, 2021, 11, 43.	4.8	47
185	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. JAMA Psychiatry, 2022, 79, 210.	11.0	47
186	White matter alterations related to P300 abnormalities in individuals at high risk for psychosis: an MRI–EEG study. Journal of Psychiatry and Neuroscience, 2011, 36, 239-248.	2.4	46
187	Longâ€acting injectable antipsychotics in early psychosis: a literature review. Microbial Biotechnology, 2013, 7, 247-254.	1.7	46
188	Bullying victimisation and paranoid ideation in people at ultra high risk for psychosis. Schizophrenia Research, 2015, 168, 68-73.	2.0	46
189	Why ultra high risk criteria for psychosis prediction do not work well outside clinical samples and what to do about it. World Psychiatry, 2017, 16, 212-213.	10.4	45
190	Gamma band oscillations in the early phase of psychosis: A systematic review. Neuroscience and Biobehavioral Reviews, 2018, 90, 381-399.	6.1	45
191	Why transition risk to psychosis is not declining at the OASIS ultra high risk service: The hidden role of stable pretest risk enrichment. Schizophrenia Research, 2018, 192, 385-390.	2.0	45
192	Psychosis Polyrisk Score (PPS) for the Detection of Individuals At-Risk and the Prediction of Their Outcomes. Frontiers in Psychiatry, 2019, 10, 174.	2.6	45
193	Neuroimaging studies of the early stages of psychosis: A critical review. European Psychiatry, 2008, 23, 237-244.	0.2	44
194	Can We Detect Psychotic-like Experiences in the General Population?. Current Pharmaceutical Design, 2012, 18, 376-385.	1.9	44
195	Modulation of motivational salience processing during the early stages of psychosis. Schizophrenia Research, 2015, 166, 17-23.	2.0	44
196	Services for people at high risk improve outcomes in patients with first episode psychosis. Acta Psychiatrica Scandinavica, 2016, 133, 76-85.	4.5	44
197	Dynamic ElecTronic hEalth reCord deTection (DETECT) of individuals at risk of a first episode of psychosis: a case-control development and validation study. The Lancet Digital Health, 2020, 2, e229-e239.	12.3	44
198	Paul Eugen Bleuler and the Birth of Schizophrenia (1908). American Journal of Psychiatry, 2008, 165, 1407-1407.	7.2	43

#	Article	IF	CITATIONS
199	Neural correlates of visuospatial working memory in the â€~at-risk mental state'. Psychological Medicine, 2010, 40, 1987-1999.	4.5	43
200	Gray matters! — Mapping the transition to psychosis. Schizophrenia Research, 2011, 133, 63-67.	2.0	43
201	Multimodal functional and structural imaging investigations in psychosis research. European Archives of Psychiatry and Clinical Neuroscience, 2012, 262, 97-106.	3.2	42
202	Diagnostic validity of ICD-10 acute and transient psychotic disorders and DSM-5 brief psychotic disorder. European Psychiatry, 2017, 45, 104-113.	0.2	41
203	Olfactory and gustatory dysfunctions in SARS-CoV-2 infection: A systematic review. Brain, Behavior, & Immunity - Health, 2021, 15, 100268.	2.5	41
204	Functional brain networks before the onset of psychosis: A prospective fMRI study with graph theoretical analysis. NeuroImage: Clinical, 2012, 1, 91-98.	2.7	40
205	Cannabis abuse and brain morphology in schizophrenia: a review of the available evidence. European Archives of Psychiatry and Clinical Neuroscience, 2013, 263, 3-13.	3.2	40
206	Predictors of functional outcome in individuals at high clinical risk for psychosis at six years follow-up. Journal of Psychiatric Research, 2015, 65, 115-123.	3.1	40
207	Forty years of structural imaging in psychosis: promises and truth. Acta Psychiatrica Scandinavica, 2016, 134, 207-224.	4.5	40
208	Lower speech connectedness linked to incidence of psychosis in people at clinical high risk. Schizophrenia Research, 2021, 228, 493-501.	2.0	40
209	A General Approach for Combining Voxel-Based Meta-Analyses Conducted in Different Neuroimaging Modalities. Current Medicinal Chemistry, 2013, 20, 462-466.	2.4	40
210	Abnormal effective connectivity and psychopathological symptoms in the psychosis high-risk state. Journal of Psychiatry and Neuroscience, 2014, 39, 239-248.	2.4	39
211	Meta-analytical prognostic accuracy of the Comprehensive Assessment of at Risk Mental States (CAARMS): The need for refined prediction. European Psychiatry, 2018, 49, 62-68.	0.2	39
212	Real World Implementation of a Transdiagnostic Risk Calculator for the Automatic Detection of Individuals at Risk of Psychosis in Clinical Routine: Study Protocol. Frontiers in Psychiatry, 2019, 10, 109.	2.6	39
213	Effect of acute tryptophan depletion on pre-frontal engagement. Psychopharmacology, 2006, 187, 486-497.	3.1	38
214	Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis. Schizophrenia Bulletin, 2017, 43, sbw110.	4.3	38
215	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). European Neuropsychopharmacology, 2019, 29, 1301-1311.	0.7	38
216	Modulation of neural response to happy and sad faces by acute tryptophan depletion. Psychopharmacology, 2007, 193, 31-44.	3.1	37

#	Article	IF	CITATIONS
217	Are we really mapping psychosis risk? Neuroanatomical signature of affective disorders in subjects at ultra high risk. Psychological Medicine, 2014, 44, 3491-3501.	4.5	37
218	Identifying children and adolescents at ultra high risk of psychosis in Italian neuropsychiatry services: a feasibility study. European Child and Adolescent Psychiatry, 2016, 25, 91-106.	4.7	37
219	Neurobiological Models of Self-Disorders in Early Schizophrenia. Schizophrenia Bulletin, 2016, 42, 874-880.	4.3	36
220	Semistructured Interview for Bipolar At Risk States (SIBARS). Psychiatry Research, 2018, 264, 302-309.	3.3	36
221	Using Natural Language Processing on Electronic Health Records to Enhance Detection and Prediction of Psychosis Risk. Schizophrenia Bulletin, 2021, 47, 405-414.	4.3	36
222	Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis. Journal of Psychiatry and Neuroscience, 2016, 41, 367-376.	2.4	36
223	Anti-depressive Therapies After Heart Transplantation. Journal of Heart and Lung Transplantation, 2006, 25, 785-793.	0.6	35
224	Relationship Between Gyrification and Functional Connectivity of the Prefrontal Cortex in Subjects at High Genetic Risk of Schizophrenia. Current Pharmaceutical Design, 2012, 18, 434-442.	1.9	35
225	Outreach and support in South-London (OASIS) 2001—2020: Twenty years of early detection, prognosis and preventive care for young people at risk of psychosis. European Neuropsychopharmacology, 2020, 39, 111-122.	0.7	35
226	Suicide, self-harm and thoughts of suicide or self-harm in infectious disease epidemics: a systematic review and meta-analysis. Epidemiology and Psychiatric Sciences, 2021, 30, e32.	3.9	35
227	Anterior cingulate pathology in the prodromal stage of schizophrenia. NeuroImage, 2008, 39, 553-554.	4.2	34
228	Glutamate and Psychosis Risk. Current Pharmaceutical Design, 2012, 18, 466-478.	1.9	34
229	Third-generation neuroimaging in early schizophrenia: Translating research evidence into clinical utility. British Journal of Psychiatry, 2012, 200, 270-272.	2.8	34
230	Longitudinal alterations in motivational salience processing in ultra-high-risk subjects for psychosis. Psychological Medicine, 2017, 47, 243-254.	4.5	34
231	Unmet needs in patients with brief psychotic disorders: Too ill for clinical high risk services and not ill enough for first episode services. European Psychiatry, 2019, 57, 26-32.	0.2	34
232	Gray Matter Volumetric Abnormalities Associated with the Onset of Psychosis. Frontiers in Psychiatry, 2012, 3, 101.	2.6	33
233	The gut-microbiome as a target for the treatment of schizophrenia: A systematic review and meta-analysis of randomised controlled trials of add-on strategies. Schizophrenia Research, 2021, 234, 58-70.	2.0	33
234	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33

#	Article	IF	CITATIONS
235	Depression After Lung Transplantation: Causes and Treatment. Lung, 2007, 185, 55-65.	3.3	32
236	Orbitofrontal response to drug-related stimuli after heroin administration. Addiction Biology, 2015, 20, 570-579.	2.6	32
237	Age-related brain structural alterations as an intermediate phenotype of psychosis. Journal of Psychiatry and Neuroscience, 2017, 42, 307-319.	2.4	32
238	Long term outcomes of acute and transient psychotic disorders: The missed opportunity of preventive interventions. European Psychiatry, 2018, 52, 126-133.	0.2	32
239	Learning from COVID-19 pandemic in northen italy: Impact on mental health and clinical care. Journal of Affective Disorders, 2020, 275, 78-79.	4.1	32
240	Toward Generalizable and Transdiagnostic Tools for Psychosis Prediction: An Independent Validation and Improvement of the NAPLS-2 Risk Calculator in the Multisite PRONIA Cohort. Biological Psychiatry, 2021, 90, 632-642.	1.3	32
241	The Relationship of Developmental Changes in White Matter to the Onset of Psychosis. Current Pharmaceutical Design, 2012, 18, 422-433.	1.9	30
242	A systematic review and metaâ€analysis of mental health service use in people who report psychotic experiences. Microbial Biotechnology, 2018, 12, 275-285.	1.7	30
243	Real-world implementation of precision psychiatry: Transdiagnostic risk calculator for the automatic detection of individuals at-risk of psychosis. Schizophrenia Research, 2021, 227, 52-60.	2.0	30
244	Associations between mental and physical conditions in children and adolescents: An umbrella review. Neuroscience and Biobehavioral Reviews, 2022, 137, 104662.	6.1	30
245	Genetic Vulnerability to Affective Psychopathology in Childhood: A Combined Voxel-Based Morphometry and Functional Magnetic Resonance Imaging Study. Biological Psychiatry, 2009, 66, 231-237.	1.3	29
246	TRANSD recommendations: improving transdiagnostic research in psychiatry. World Psychiatry, 2019, 18, 361-362.	10.4	29
247	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. Frontiers in Psychiatry, 2019, 10, 345.	2.6	29
248	Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care. EClinicalMedicine, 2020, 28, 100578.	7.1	29
249	Prevalence of Individuals at Clinical High-Risk of Psychosis in the General Population and Clinical Samples: Systematic Review and Meta-Analysis. Brain Sciences, 2021, 11, 1544.	2.3	29
250	Global population attributable fraction of potentially modifiable risk factors for mental disorders: a meta-umbrella systematic review. Molecular Psychiatry, 2022, 27, 3510-3519.	7.9	29
251	Conceptual issues in psychiatric neuroimaging. Current Opinion in Psychiatry, 2006, 19, 608-612.	6.3	28
252	Cognitive Remediation in the Early Course of Schizophrenia: A Critical Review. Current Pharmaceutical Design, 2012, 18, 534-541.	1.9	28

#	Article	IF	CITATIONS
253	Polyunsaturated fatty acids in emerging psychosis: a safer alternative?. Microbial Biotechnology, 2014, 8, 199-208.	1.7	28
254	Medial frontal gyrus alterations in schizophrenia: Relationship with duration of illness and executive dysfunction. Psychiatry Research - Neuroimaging, 2015, 231, 103-110.	1.8	28
255	Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit. Schizophrenia Research, 2021, 227, 10-17.	2.0	28
256	The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: Systematic review and meta-analysis. Journal of Affective Disorders, 2021, 280, 409-431.	4.1	28
257	Universal and Selective Interventions to Prevent Poor Mental Health Outcomes in Young People: Systematic Review and Meta-analysis. Harvard Review of Psychiatry, 2021, 29, 196-215.	2.1	28
258	Natural Language Processing markers in first episode psychosis and people at clinical high-risk. Translational Psychiatry, 2021, 11, 630.	4.8	28
259	Why are psychiatric imaging methods clinically unreliable? Conclusions and practical guidelines for authors, editors and reviewers. Behavioral and Brain Functions, 2012, 8, 46.	3.3	27
260	Risk and protective factors for anxiety and obsessive-compulsive disorders: an umbrella review of systematic reviews and meta-analyses. Psychological Medicine, 2020, 50, 1300-1315.	4.5	27
261	Brain Diffusion Changes in Emerging Psychosis and the Impact of State-Dependent Psychopathology. NeuroSignals, 2015, 23, 71-83.	0.9	26
262	Intensive community outreach for those at ultra high risk of psychosis: dilution, not solution. Lancet Psychiatry,the, 2016, 3, 18.	7.4	26
263	Diagnostic and Prognostic Significance of DSM-5 Attenuated Psychosis Syndrome in Services for Individuals at Ultra High Risk for Psychosis. Schizophrenia Bulletin, 2018, 44, 264-275.	4.3	26
264	Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis. Neuropsychopharmacology, 2019, 44, 1300-1309.	5.4	26
265	Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis. Epidemiology and Psychiatric Sciences, 2022, 31, e9.	3.9	26
266	Episodic Memory Dysfunction in Individuals at High-Risk of Psychosis: A Systematic Review of Neuropsychological and Neurofunctional Studies. Current Pharmaceutical Design, 2012, 18, 443-458.	1.9	25
267	Longitudinal outcome of attenuated positive symptoms, negative symptoms, functioning and remission in people at clinical high risk for psychosis: a meta-analysis. EClinicalMedicine, 2021, 36, 100909.	7.1	25
268	Pan-London Network for Psychosis-Prevention (PNP). Frontiers in Psychiatry, 2019, 10, 707.	2.6	24
269	Diagnosis, prognosis, and treatment of brief psychotic episodes: a review and research agenda. Lancet Psychiatry,the, 2022, 9, 72-83.	7.4	24
270	Effect of image analysis software on neurofunctional activation during processing of emotional human faces. Journal of Clinical Neuroscience, 2010, 17, 311-314.	1.5	23

#	Article	IF	CITATIONS
271	Unmet needs for treatment in 102 individuals with brief and limited intermittent psychotic symptoms (BLIPS): implications for current clinical recommendations. Epidemiology and Psychiatric Sciences, 2020, 29, e67.	3.9	23
272	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	4.1	23
273	Integrating the negative psychotic symptoms in the high risk criteria for the prediction of psychosis. Medical Hypotheses, 2007, 69, 959-960.	1.5	22
274	The Hype Cycle of the Clinical High Risk State for Psychosis: The Need of a Refined Approach. Schizophrenia Bulletin, 2018, 44, 250-253.	4.3	22
275	The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic. Journal of Affective Disorders, 2022, 299, 393-407.	4.1	22
276	Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response. Journal of the American Academy of Child and Adolescent Psychiatry, 2023, 62, 151-168.	0.5	22
277	Potential therapeutical effects of cannabidiol in children with pharmacoresistant epilepsy. Medical Hypotheses, 2007, 68, 920-921.	1.5	21
278	Economic Impact of Early Detection and Early Intervention of Psychosis. Current Pharmaceutical Design, 2012, 18, 592-595.	1.9	21
279	Clinical-learning versus machine-learning for transdiagnostic prediction of psychosis onset in individuals at-risk. Translational Psychiatry, 2019, 9, 259.	4.8	21
280	Cingulate Volume Abnormalities in Emerging Psychosis. Current Pharmaceutical Design, 2012, 18, 495-504.	1.9	21
281	Differential expression of MicroRNAs in Alzheimer's disease: a systematic review and meta-analysis. Molecular Psychiatry, 2022, 27, 2405-2413.	7.9	21
282	â€~Truman' signs and vulnerability to psychosis. British Journal of Psychiatry, 2008, 193, 168-168.	2.8	20
283	Lifestyles and Cardiovascular Risk in Individuals With Functional Psychoses. Perspectives in Psychiatric Care, 2009, 45, 87-99.	1.9	20
284	The Ultra High Risk Approach to Define Psychosis Risk. Current Pharmaceutical Design, 2012, 18, 346-350.	1.9	20
285	Gender differences in clinical presentation and illicit substance use during first episode psychosis: a natural language processing, electronic case register study. BMJ Open, 2021, 11, e042949.	1.9	20
286	A systematic review and meta-analysis of structural and functional brain alterations in individuals with genetic and clinical high-risk for psychosis and bipolar disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 117, 110540.	4.8	20
287	Reliability and Validity of the Comprehensive Assessment of the at Risk Mental State, Italian Version (CAARMS-I). Current Pharmaceutical Design, 2012, 18, 386-391.	1.9	19
288	Formal thought disorder in people at ultra-high risk of psychosis. BJPsych Open, 2017, 3, 165-170.	0.7	19

#	Article	IF	CITATIONS
289	Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack. Journal of Visualized Experiments, 2020, , .	0.3	19
290	Association between autism spectrum disorder and inflammatory bowel disease: A systematic review and metaâ€analysis. Autism Research, 2022, 15, 340-352.	3.8	19
291	Striatal molecular alterations in HD gene carriers: a systematic review and meta-analysis of PET studies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 185-196.	1.9	18
292	Proportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysis. European Psychiatry, 2021, 64, e69.	0.2	18
293	Getting Old With a New Heart: Impact of Age on Depression and Quality of Life in Long-term Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2007, 26, 544-548.	0.6	17
294	Neural correlates of movement generation in the â€~atâ€risk mental state'. Acta Psychiatrica Scandinavica, 2010, 122, 295-301.	4.5	17
295	A Case of a College Student Presenting With Mild Mental Health Problems. JAMA Psychiatry, 2018, 75, 1298.	11.0	17
296	Psychotic experiences, psychiatric comorbidity and mental health need in the general population: a cross-sectional and cohort study in Southeast London. Psychological Medicine, 2021, 51, 147-157.	4.5	17
297	Viewpoint   European COVID-19 exit strategy for people with severe mental disorders: Too little, but not yet too late. Brain, Behavior, and Immunity, 2021, 94, 15-17.	4.1	17
298	Polyunsaturated Fatty Acids in Emerging Psychosis. Current Pharmaceutical Design, 2012, 18, 576-591.	1.9	16
299	Transdiagnostic Individualized Clinically Based Risk Calculator for the Detection of Individuals at Risk and the Prediction of Psychosis: Model Refinement Including Nonlinear Effects of Age. Frontiers in Psychiatry, 2019, 10, 313.	2.6	16
300	Intranasal oxytocin increases heart-rate variability in men at clinical high risk for psychosis: a proof-of-concept study. Translational Psychiatry, 2020, 10, 227.	4.8	16
301	Association between mental disorders and somatic conditions: protocol for an umbrella review. Evidence-Based Mental Health, 2020, 23, 135-139.	4.5	16
302	E-Clinical High Risk for Psychosis: Viewpoint on Potential of Digital Innovations for Preventive Psychiatry. JMIR Mental Health, 2019, 6, e14581.	3.3	16
303	The effects of antipsychotics on brain structure: what have we learnt from structural imaging of schizophrenia?. Psychological Medicine, 2009, 39, 1781-1782.	4.5	15
304	Franco Basaglia (1924—1980): Three Decades (1979—2009) as a Bridge Between the Italian and Brazilian Mental Health Reform. International Journal of Social Psychiatry, 2011, 57, 100-103.	3.1	15
305	Neighbourhood deprivation is positively associated with detection of the ultra-high risk (UHR) state for psychosis in South East London. Schizophrenia Research, 2018, 192, 371-376.	2.0	15
306	Transdiagnostic individualized clinically-based risk calculator for the automatic detection of individuals at-risk and the prediction of psychosis: external replication in 2,430,333 US patients. Translational Psychiatry, 2020, 10, 364.	4.8	15

#	Article	IF	CITATIONS
307	Cortical gray matter reduction precedes transition to psychosis in individuals at clinical high-risk for psychosis: A voxel-based meta-analysis. Schizophrenia Research, 2021, 232, 98-106.	2.0	15
308	Longitudinal Course of Depressive, Anxiety, and Posttraumatic Stress Disorder Symptoms After Heart Surgery: A Meta-Analysis of 94 Studies. Psychosomatic Medicine, 2021, 83, 85-93.	2.0	15
309	Second Life virtual world: A heaven for autistic people?. Medical Hypotheses, 2008, 71, 980-981.	1.5	14
310	Superior temporal gray and white matter changes in schizophrenia or antipsychotic related effects?. Schizophrenia Research, 2009, 113, 109-110.	2.0	14
311	The Enduring Search for the Koplik Spots of Psychosis. JAMA Psychiatry, 2015, 72, 863.	11.0	14
312	Psychiatric and neuropsychiatric syndromes and COVID-19 – Authors' reply. Lancet Psychiatry,the, 2020, 7, 664-665.	7.4	14
313	Risk and protective factors for mental disorders with onset in childhood/adolescence: An umbrella review of published meta-analyses of observational longitudinal studies. Neuroscience and Biobehavioral Reviews, 2021, 120, 565-573.	6.1	14
314	Risk and protective factors for cannabis, cocaine, and opioid use disorders: An umbrella review of meta-analyses of observational studies. Neuroscience and Biobehavioral Reviews, 2021, 126, 243-251.	6.1	14
315	Public health primary prevention implemented by clinical high-risk services for psychosis. Translational Psychiatry, 2022, 12, 43.	4.8	14
316	Understanding source monitoring subtypes and their relation to psychosis: a systematic review and metaâ€analysis. Psychiatry and Clinical Neurosciences, 2022, 76, 162-171.	1.8	14
317	Dysbindin modulates brain function during visual processing in children. NeuroImage, 2010, 49, 817-822.	4.2	13
318	Hippocampal volume correlates with attenuated negative psychotic symptoms irrespective of antidepressant medication. NeuroImage: Clinical, 2015, 8, 230-237.	2.7	13
319	Prevalence and implications of Truman symptoms in subjects at ultra high risk for psychosis. Psychiatry Research, 2016, 238, 270-276.	3.3	13
320	An initial investigation of abnormal bodily phenomena in subjects at ultra high risk for psychosis: Their prevalence and clinical implications. Comprehensive Psychiatry, 2016, 66, 39-45.	3.1	13
321	Development and Validation of a Dynamic Risk Prediction Model to Forecast Psychosis Onset in Patients at Clinical High Risk. Schizophrenia Bulletin, 2019, 46, 252-260.	4.3	13
322	Risk and Protective Factors for Personality Disorders: An Umbrella Review of Published Meta-Analyses of Case–Control and Cohort Studies. Frontiers in Psychiatry, 2021, 12, 679379.	2.6	13
323	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis. Molecular Psychiatry, 2022, 27, 3670-3678.	7.9	13
324	Effects of Antipsychotics on Dentate Gyrus Stem Cell Proliferation and Survival in Animal Models: A Critical Update. Neural Plasticity, 2012, 2012, 1-12.	2.2	12

#	Article	IF	CITATIONS
325	Genetic Vulnerability to Psychosis and Cortical Function: Epistatic Effects between DAAO and G72. Current Pharmaceutical Design, 2012, 18, 510-517.	1.9	12
326	Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?. Current Pharmaceutical Design, 2012, 18, 416-421.	1.9	12
327	White matter pathology – an endophenotype for bipolar disorder?. BMC Psychiatry, 2012, 12, 138.	2.6	12
328	Negative Psychosis Prevention Trials. JAMA Psychiatry, 2017, 74, 651.	11.0	12
329	World/self ambivalence: A shared mechanism in different subsets of psychotic experiences? Linking symptoms with resting-state fMRI. Psychiatry Research - Neuroimaging, 2020, 299, 111068.	1.8	12
330	Prognostic Accuracy of DSM-5 Attenuated Psychosis Syndrome in Adolescents: Prospective Real-World 5-Year Cohort Study. Schizophrenia Bulletin, 2021, 47, 1663-1673.	4.3	12
331	The Vulnerability to Schizophrenia Mainstream Research Paradigms and Phenomenological Directions. Current Pharmaceutical Design, 2012, 18, 338-345.	1.9	11
332	The impact of delivering <scp>GP</scp> training on the clinical high risk and firstâ€episode psychosis on referrals and pathways to care. Microbial Biotechnology, 2015, 9, 459-466.	1.7	11
333	Sensory gating deficits in the attenuated psychosis syndrome. Schizophrenia Research, 2015, 161, 277-282.	2.0	11
334	The relationship between ethnicity and service access, treatment uptake and the incidence of psychosis among people at ultra high risk for psychosis. Psychiatry Research, 2019, 272, 618-627.	3.3	11
335	Real-world digital implementation of the Psychosis Polyrisk Score (PPS): A pilot feasibility study. Schizophrenia Research, 2020, 226, 176-183.	2.0	11
336	Real-World Clinical Outcomes Two Years After Transition to Psychosis in Individuals at Clinical High Risk: Electronic Health Record Cohort Study. Schizophrenia Bulletin, 2020, 46, 1114-1125.	4.3	11
337	Evaluation of variability in individual response to treatments in the clinical high-risk state for psychosis: A meta-analysis. Schizophrenia Research, 2021, 227, 20-27.	2.0	11
338	Egas Moniz (1875–1955), the father of psychosurgery. British Journal of Psychiatry, 2008, 193, 50-50.	2.8	10
339	Ethical Implications for Clinical Practice and Future Research in "At Risk" Individuals. Current Pharmaceutical Design, 2012, 18, 606-612.	1.9	10
340	Impact on the Onset of Psychosis of a Polygenic Schizophrenia-Related Risk Score and Changes in White Matter Volume. Cellular Physiology and Biochemistry, 2018, 48, 1201-1214.	1.6	10
341	Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach. Scientific Reports, 2019, 9, 8516.	3.3	10
342	Aripiprazole monotherapy as transdiagnostic intervention for the treatment of mental disorders: An umbrella review according to TRANSD criteria. European Neuropsychopharmacology, 2020, 41, 16-27.	0.7	10

Paolo Fusar-Poli

#	Article	IF	CITATIONS
343	Acute oxytocin effects in inferring others' beliefs and social emotions in people at clinical high risk for psychosis. Translational Psychiatry, 2020, 10, 203.	4.8	10
344	Third external replication of an individualised transdiagnostic prediction model for the automatic detection of individuals at risk of psychosis using electronic health records. Schizophrenia Research, 2021, 228, 403-409.	2.0	10
345	Structural Brain Volumes of Individuals at Clinical High Risk for Psychosis: A Meta-analysis. Biological Psychiatry Global Open Science, 2022, 2, 147-152.	2.2	10
346	Heterogeneity in the Assessment of the At-Risk Mental State for Psychosis. Psychiatric Services, 2008, 59, 813-813.	2.0	10
347	Real-World Implementation of Precision Psychiatry: A Systematic Review of Barriers and Facilitators. Brain Sciences, 2022, 12, 934.	2.3	10
348	Franco Basaglia, 1924–1980. American Journal of Psychiatry, 2008, 165, 968-968.	7.2	9
349	Johann Cristian Reil on the 200th anniversary of the first description of the insula (1809). Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1409-1409.	1.9	9
350	Neurophysiological response to emotional faces with increasing intensity of fear: A skin conductance response study. Journal of Clinical Neuroscience, 2009, 16, 981-982.	1.5	9
351	Philosophical Issues in the Prodromal Phase of Psychosis. Current Pharmaceutical Design, 2012, 18, 596-605.	1.9	9
352	Predictive power of attenuated psychosis syndrome: Is it really low? The case of mild cognitive impairment. Schizophrenia Research, 2012, 135, 192-193.	2.0	9
353	Neuropsychopharmacology of auditory hallucinations: insights from pharmacological functional MRI and perspectives for future research. Expert Review of Neurotherapeutics, 2013, 13, 23-36.	2.8	9
354	Short clinically-based prediction model to forecast transition to psychosis in individuals at clinical high risk state. European Psychiatry, 2019, 58, 72-79.	0.2	9
355	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
356	Development of a probability calculator for psychosis risk in children, adolescents, and young adults. Psychological Medicine, 2022, 52, 3159-3167.	4.5	9
357	Promoting good mental health in the whole population: The new frontier. European Neuropsychopharmacology, 2022, 55, 8-10.	0.7	9
358	Higher levels of mental wellbeing predict lower risk of common mental disorders in the Danish general population. Mental Health and Prevention, 2022, 26, 200233.	1.3	9
359	Maurice Merleauâ€Ponty and the "Embodied Subjectivity―(1908–61). Medical Anthropology Quarterly, 2009, 23, 91-93.	1.4	8
360	Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis. Frontiers in Psychiatry, 2019, 10, 254.	2.6	8

#	Article	IF	CITATIONS
361	Neurochemical effects of oxytocin in people at clinical high risk for psychosis. European Neuropsychopharmacology, 2019, 29, 601-615.	0.7	8
362	Early Intervention Services for First Episode of Psychosis in South London and the Maudsley (SLaM): 20 Years of Care and Research for Young People. Frontiers in Psychiatry, 2020, 11, 577110.	2.6	8
363	Developing and Validating an Individualized Clinical Prediction Model to Forecast Psychotic Recurrence in Acute and Transient Psychotic Disorders: Electronic Health Record Cohort Study. Schizophrenia Bulletin, 2021, 47, 1695-1705.	4.3	8
364	Why Is Psychiatric Imaging Clinically Unreliable? Epistemological Perspectives in Clinical Neuroscience. Psychotherapy and Psychosomatics, 2009, 78, 320-321.	8.8	7
365	Abnormal thalamic glutamate and liability to psychosis: State or trait marker?. Schizophrenia Research, 2009, 115, 94-95.	2.0	7
366	Neurophysiological Alterations in the Prepsychotic Phases. Current Pharmaceutical Design, 2012, 18, 479-485.	1.9	7
367	Cannabis Abuse and Vulnerability to Psychosis: Targeting Preventive Services. Current Pharmaceutical Design, 2012, 18, 542-549.	1.9	7
368	People meeting ultra high risk for psychosis criteria in the community. World Psychiatry, 2017, 16, 322-323.	10.4	7
369	Pattern of activation during delayed matching to sample task predicts functional outcome in people at ultra high risk for psychosis. Schizophrenia Research, 2017, 181, 86-93.	2.0	7
370	Towards a framework for good outcome in people at clinical high risk for psychosis: A Delphi consensus study. Schizophrenia Research, 2019, 208, 209-216.	2.0	7
371	DSM-5 Attenuated Psychosis Syndrome in Adolescents Hospitalized With Non-psychotic Psychiatric Disorders. Frontiers in Psychiatry, 2020, 11, 568982.	2.6	7
372	Genetic Variation and Autism: A Field Synopsis and Systematic Meta-Analysis. Brain Sciences, 2020, 10, 692.	2.3	7
373	Transition to psychosis in randomized clinical trials of individuals at clinical high risk of psychosis compared to observational cohorts: a systematic review and meta-analysis. European Psychiatry, 2021, 64, e51.	0.2	7
374	Suicide, self-harm and thoughts of suicide or self-harm in infectious disease epidemics: a systematic review and meta-analysis – CORRIGENDUM. Epidemiology and Psychiatric Sciences, 2021, 30, .	3.9	7
375	A Pilot Study on Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. Brain Sciences, 2021, 11, 860.	2.3	7
376	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. European Neuropsychopharmacology, 2022, 55, 112-157.	0.7	7
377	Psychosis and substance abuse increase the COVID-19 mortality risk. Psychological Medicine, 2023, 53, 4236-4244.	4.5	7
378	Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis. Translational Psychiatry, 2022, 12, 198.	4.8	7

#	Article	IF	CITATIONS
379	Marfan syndrome and liability to psychosis. Medical Hypotheses, 2007, 68, 1173-1174.	1.5	6
380	One Century of Allgemeine Psychopathologie (1913 to 2013) by Karl Jaspers. Schizophrenia Bulletin, 2013, 39, 268-269.	4.3	6
381	The Provision of Education and Employment Support At the Outreach and Support in South London (OASIS) Service for People at Clinical High Risk for Psychosis. Frontiers in Psychiatry, 2019, 10, 799.	2.6	6
382	Methodological Biases in CBT Trial—Commentary: Modular Cognitive-Behavioral Therapy for Affective Symptoms in Young Individuals at Ultra-High Risk of First Episode of Psychosis: Randomized Controlled Trial. Frontiers in Psychiatry, 2020, 11, 394.	2.6	6
383	Risk and protective factors for alcohol and tobacco related disorders: An umbrella review of observational studies. Neuroscience and Biobehavioral Reviews, 2021, 121, 20-28.	6.1	6
384	Can we increase the subjective well-being of the general population? An umbrella review of the evidence. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 50-64.	1.8	6
385	Early intervention in psychosis during the COVID-19 pandemic: Maudsley recommendations. European Neuropsychopharmacology, 2021, 47, 130-135.	0.7	6
386	Linking autism, regression and Landau–Kleffner syndrome: Integrative role of nerve growth factor. Medical Hypotheses, 2007, 68, 1178-1179.	1.5	5
387	Multimodal functional imaging investigation before and after the onset of psychosis. International Journal of Neuropsychopharmacology, 2009, 12, 579.	2.1	5
388	Examining serviceâ€user perspectives for the development of a good outcome checklist for individuals at clinical high risk for psychosis. Microbial Biotechnology, 2021, 15, 606-615.	1.7	5
389	Assessment of Psychotic Symptoms in Individuals Exposed to Very High or Extreme Altitude: A Field Study. High Altitude Medicine and Biology, 2021, 22, 369-378.	0.9	5
390	Lack of robust metaâ€analytic evidence to favour cognitive behavioural therapy for prevention of psychosis. World Psychiatry, 2021, 20, 443-444.	10.4	5
391	Clinical outcomes in brief psychotic episodes: a systematic review and meta-analysis. Epidemiology and Psychiatric Sciences, 2021, 30, .	3.9	5
392	Focusing on Comorbidity—A Novel Meta-Analytic Approach and Protocol to Disentangle the Specific Neuroanatomy of Co-occurring Mental Disorders. Frontiers in Psychiatry, 2021, 12, 807839.	2.6	5
393	Development of the Korea-Polyenvironmental Risk Score for Psychosis. Psychiatry Investigation, 2022, 19, 197-206.	1.6	5
394	Environmental risk factors, protective factors, and biomarkers for postpartum depressive symptoms: an umbrella review. Neuroscience and Biobehavioral Reviews, 2022, 140, 104761.	6.1	5
395	Can acute tryptophan depletion modulate brain function in absence of behavioural effects?. Medical Hypotheses, 2007, 68, 722.	1.5	4
396	Insular pathology in the at-risk mental state. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 254-255.	3.2	4

#	Article	IF	CITATIONS
397	Julius Wagner-Jauregg, 1857–1940. American Journal of Psychiatry, 2009, 166, 409-409.	7.2	4
398	Distinct Effects of D9-tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing. European Psychiatry, 2009, 24, .	0.2	4
399	Predicting the development of schizophrenia. British Journal of Psychiatry, 2012, 200, 254-255.	2.8	4
400	Prison and Community Populations at Ultra-High Risk of Psychosis: Differences and Challenges for Service Provision. Psychiatric Services, 2016, 67, 990-995.	2.0	4
401	The Psychosis High-Risk State. Key Issues in Mental Health, 2016, , 55-68.	0.6	4
402	Proportion of young people in the general population consulting general practitioners: Potential for mental health screening and prevention. Microbial Biotechnology, 2020, 14, 631-635.	1.7	4
403	T97. REAL WORLD IMPLEMENTATION OF A TRANSDIAGNOSTIC RISK CALCULATOR FOR THE AUTOMATIC DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN CLINICAL ROUTINE. Schizophrenia Bulletin, 2020, 46, S268-S268.	4.3	4
404	Towards standardising the assessment of good outcome in people at clinical high risk for psychosis: A collaborative approach. Schizophrenia Research, 2020, 223, 361-362.	2.0	4
405	New Electronic Health Records Screening Tools to Improve Detection of Emerging Psychosis. Frontiers in Psychiatry, 2021, 12, 698406.	2.6	4
406	ITAlian Partnership for Psychosis Prevention (ITAPP): improving the mental health of young people. European Psychiatry, 2021, 64, 1-21.	0.2	4
407	Impact of data extraction errors in meta-analyses on the association between depression and peripheral inflammatory biomarkers: an umbrella review. Psychological Medicine, 2023, 53, 2017-2030.	4.5	4
408	Roger Keith "Syd―Barrett (1946–2006). American Journal of Psychiatry, 2007, 164, 1028-1028.	7.2	3
409	Imaging Genomics – An integrative approach to understand the biological susceptibility for schizophrenia. Medical Hypotheses, 2007, 68, 1426.	1.5	3
410	Quetiapine as a first-choice agent in subjects at high-risk to psychosis?. Medical Hypotheses, 2007, 69, 230.	1.5	3
411	Love and brain: From mereological fallacy to "folk―neuroimaging. Psychiatry Research - Neuroimaging, 2007, 154, 285-286.	1.8	3
412	Albert Hofmann, the Father of LSD (1906–2008). Neuropsychobiology, 2008, 58, 53-54.	1.9	3
413	Brain Damage. Academic Medicine, 2008, 83, 742.	1.6	3
414	From Brentano to mirror neurons: Bridging phenomenology and clinical neuroscience. Psychiatry Research - Neuroimaging, 2010, 183, 245-246.	1.8	3

#	Article	IF	CITATIONS
415	Letter to the Editor: Mind the translation gap: problems in the implementation of early intervention services. Psychological Medicine, 2010, 40, 171-172.	4.5	3
416	Biochemical Markers of Impending Psychosis. Current Pharmaceutical Design, 2012, 18, 505-509.	1.9	3
417	Gray matter pathology of hippocampus – A specific endophenotype for schizophrenia?. Psychiatry Research - Neuroimaging, 2012, 202, 273-274.	1.8	3
418	Psychosocial Intervention Without Antipsychotic Medication for Brief Psychotic Episodes?. Schizophrenia Bulletin Open, 2020, 1, .	1.7	3
419	The case for improved transdiagnostic detection of first-episode psychosis: Electronic health record cohort study. Schizophrenia Research, 2021, 228, 547-554.	2.0	3
420	Early detection of bipolar disorders and treatment recommendations for help-seeking adolescents and young adults: Findings of the Early Detection and Intervention Center Dresden. International Journal of Bipolar Disorders, 2021, 9, 23.	2.2	3
421	Manifesto for an ECNP Neuromodulation Thematic Working Group (TWG): Non-invasive brain stimulation as a new Super-subspecialty. European Neuropsychopharmacology, 2021, 52, 72-83.	0.7	3
422	Pseudohallucinations Versus True Hallucinations in Prodromal Psychosis. Journal of Clinical Psychiatry, 2009, 70, 1056-1057.	2.2	3
423	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 201-219.	2.2	3
424	Commentary. Academic Medicine, 2007, 82, 1109.	1.6	2
425	Anxiety and depression after lung transplantation: Mirtazapine as a first-choice agent?. Journal of Psychosomatic Research, 2007, 62, 101.	2.6	2
426	Memantine as a neuroprotective agent in early phases of psychosis. Medical Hypotheses, 2007, 68, 459-460.	1.5	2
427	Can neuroimaging reduce social stigma in schizophrenia?. Medical Hypotheses, 2007, 69, 457.	1.5	2
428	Uncovering the neural correlates of the ketogenic diet: The contribution of functional neuroimaging. Medical Hypotheses, 2007, 69, 705-706.	1.5	2
429	Targeting the effects of omega-3 and omega-6 fatty acid supplementation on schizophrenic spectrum disorders: Role of neuroimaging. Medical Hypotheses, 2007, 69, 466-467.	1.5	2
430	Pooling of data in psychiatric neuroimaging: A bridge towards clinical neuroimaging?. European Psychiatry, 2007, 22, 265-265.	0.2	2
431	Differential Diagnosis Between the Early Onset of Schizophrenia and Bipolar Disorder: <i>Potential Role of Neuroimaging</i> . CNS Spectrums, 2008, 13, 363-364.	1.2	2
432	Bupropion and Panic Disorder: Case Report and Review of the Literature. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, E47-E50.	1.8	2

#	Article	IF	CITATIONS
433	Editorial [Prodromal Psychosis: Diagnosis and Treatment (Executive Guest Editor: Paolo Fusar-Poli)]. Current Pharmaceutical Design, 2012, 18, 337-337.	1.9	2
434	Response to Spencer et al. Letter. American Journal of Psychiatry, 2012, 169, 666-666.	7.2	2
435	A General Approach for Combining Voxel-Based Meta-Analyses Conducted in Different Neuroimaging Modalities. Current Medicinal Chemistry, 2013, 20, 462-466.	2.4	2
436	Emergency department and early detection of adolescents and young adults at risk of developing mental disorders: an exploratory study. Research in Psychotherapy: Psychopathology, Process and Outcome, 2020, 23, 459.	0.8	2
437	Antipsychotics and Attenuated Psychosis Syndrome: Transdiagnostic assessment and discontinuation strategies. Schizophrenia Research, 2022, 243, 402-404.	2.0	2
438	OUP accepted manuscript. Schizophrenia Bulletin, 2021, , .	4.3	2
439	Establishing a business case for setting up early detection services for preventing psychosis. BJPsych Bulletin, 2023, 47, 156-165.	1.1	2
440	Associating Violence With Schizophrenia—Risks and Biases. JAMA Psychiatry, 2022, 79, 738.	11.0	2
441	Is a DNA sequence variation of the gene protocadherin Y a possible explanation for the sixfold higher risk to develop schizophrenia in moroccan males?. Medical Hypotheses, 2007, 69, 694.	1.5	1
442	DOPAMINERGIC MODULATION OF PREFRONTAL FUNCTIONING IN SUBJECTS AT CLINICAL RISK FOR PSYCHOSIS: A COMBINED PET-fMRI STUDY. Schizophrenia Research, 2008, 102, 30.	2.0	1
443	Successful antidepressive treatment with mirtazapine following lung transplantation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1745-1746.	4.8	1
444	Albert Hofmann. Journal of Clinical Psychopharmacology, 2008, 28, 484.	1.4	1
445	Can neuroimaging prove that schizophrenia is a brain disease? A radical hypothesis. Medical Hypotheses, 2009, 73, 855-856.	1.5	1
446	P.3.02 Opposite neural effects of the main psychoactive ingredients of cannabis —implications for therapeutics. European Neuropsychopharmacology, 2009, 19, S63-S64.	0.7	1
447	Development of a Self-Administered Questionnaire to Detect Psychosis at High Altitude: The HAPSY Questionnaire. High Altitude Medicine and Biology, 2019, 20, 352-360.	0.9	1
448	Neuroimaging and the At-Risk Mental State. , 2019, , 219-265.		1
449	Can we increase the subjective well-being of the general population? An umbrella review of the evidence. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 50-64.	0.3	1
450	Relapse prevention in schizophrenia. Lancet Psychiatry,the, 2022, 9, e13.	7.4	1

26

#	Article	IF	CITATIONS
451	No Meta-analytic Effect of Age on Probability of Developing Psychosis in Individuals at Clinical High Risk. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, , .	0.5	1
452	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. Frontiers in Psychiatry, 2022, 13, 828376.	2.6	1
453	Perceived Family Functioning Profile in Adolescents at Clinical High Risk for Psychosis: Rigidity as a Possible Preventive Target. Frontiers in Psychiatry, 2022, 13, 861201.	2.6	1
454	Associations of presenting symptoms and subsequent adverse clinical outcomes in people with unipolar depression: a prospective natural language processing (NLP), transdiagnostic, network analysis of electronic health record (EHR) data. BMJ Open, 2022, 12, e056541.	1.9	1
455	Clinical high at-risk mental state in young subjects accessing a mental disorder prevention service in Italy. Psychiatry Research, 2022, 316, 114710.	3.3	1
456	P.3.d.013 Correlation between acute atypical antipsychotic treatment and cognitive functioning in first episode psychosis. European Neuropsychopharmacology, 2006, 16, S436.	0.7	0
457	Socioeconomic provisions for specialist training in Italy and the UK: integrating the differences. Postgraduate Medical Journal, 2006, 82, 810-812.	1.8	0
458	Paired associate learning in subjects at risk for psychosis: fMRI study. European Psychiatry, 2007, 22, S314.	0.2	0
459	NEURAL CORRELATES OF VERBAL EPISODIC MEMORY IN THE AT RISK MENTAL STATE. Schizophrenia Research, 2008, 102, 29-30.	2.0	0
460	P.3.21 Delta-9-tetrahydrocannabinol modulates activity in parahippocampal cortex and ventral striatum during memory processing. European Neuropsychopharmacology, 2008, 18, s80.	0.7	0
461	P.1.e.020 Effects of cannabis ingredients in the temporal cortex – neural basis for potential antipsychotic effect of cannabidiol. European Neuropsychopharmacology, 2008, 18, S270-S271.	0.7	0
462	Opposite Neural Effects of the Main Psychoactive Ingredients of Cannabis- Neural Basis for Potential Therapeutic Effects of Cannabidiol. European Psychiatry, 2009, 24, .	0.2	0
463	Editorial [Hot Topic: Perspectives in Psychopharmacological Neuroimaging (Executive Editor: Paolo) Tj ETQq1 1 C	).784314 1.9	rgBT /Overloc
464	Comment on "Schizophrenia, brain disease and meta-analyses: Integrating the pieces and testing Fusar-Poli's hypothesis― Medical Hypotheses, 2010, 74, 395-396.	1.5	0
465	P.3.019 A meta-analysis of neuroimaging predictors of transition to psychosis. European Neuropsychopharmacology, 2010, 20, S78.	0.7	0
466	Sabina Spielrein. American Journal of Psychiatry, 2012, 169, 21-21.	7.2	0
467	Presynaptic dopamine alterations in schizophrenia: Functional or structural defect?. Psychiatry Research - Neuroimaging, 2012, 202, 271-272.	1.8	0
468	Poster #184 CANNABIS USE IN PATIENTS AT CLINICAL HIGH RISK OF PSYCHOSIS: IMPACT ON PRODROMAL SYMPTOMS AND TRANSITION TO PSYCHOSIS – A SYSTEMATIC REVIEW. Schizophrenia Research, 2012, 136, S347.	2.0	0

#	Article	IF	CITATIONS
469	THALAMIC GLUTAMATE LEVELS AS A PREDICTOR OF CORTICAL RESPONSE DURING EXECUTIVE FUNCTIONING IN SUBJECTS AT HIGH RISK FOR PSYCHOSIS. Schizophrenia Research, 2012, 136, S34.	2.0	0
470	ALTERATIONS IN BRAIN STRUCTURE, FUNCTION AND CHEMISTRY PRIOR TO THE ONSET OF PSYCHOSIS. Schizophrenia Research, 2012, 136, S55.	2.0	0
471	Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. , 2013, , 149-178.		0
472	THE PSYCHOSIS HIGH RISK STATE: IS IT VALID?. Schizophrenia Research, 2014, 153, S23-S24.	2.0	0
473	Gray Matter Reductions in Cortical Midline Structures Related to Basic Self Disturbances in People at "ultra High Risk―for Psychosis. European Psychiatry, 2015, 30, 297.	0.2	0
474	Authors' reply. British Journal of Psychiatry, 2016, 208, 197-198.	2.8	0
475	34.2 IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS IN SECONDARY MENTAL HEALTH CARE. Schizophrenia Bulletin, 2018, 44, S56-S57.	4.3	0
476	T122. UNMET NEEDS IN PATIENTS WITH ACUTE TRANSIENT PSYCHOTIC DISORDERS (ATPD): ANALYSIS OF PATHWAYS TO CARE: AN 8 YEARS FOLLOW-UP STUDY. Schizophrenia Bulletin, 2018, 44, S162-S163.	4.3	0
477	S126. GOOD OUTCOME IN INDIVIDUALS AT ULTRA-HIGH RISK (UHR) OF DEVELOPING PSYCHOSIS: A DELPHI STUDY. Schizophrenia Bulletin, 2018, 44, S374-S374.	4.3	Ο
478	Response to the commentary by Buoli et al., EURPSY-D-18-00265. European Psychiatry, 2018, 54, 100-101.	0.2	0
479	34. IMPROVING THE DETECTION OF INDIVIDUALS AT RISK OF PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S55-S56.	4.3	0
480	F256. CAN WE REDUCE THE DURATION OF UNTREATED PSYCHOSIS?. Schizophrenia Bulletin, 2018, 44, S323-S323.	4.3	0
481	S149. EFFECTS OF INTRANASAL OXYTOCIN ON RESTING CEREBRAL BLOOD FLOW IN PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S383-S383.	4.3	0
482	Specialized services for individuals at clinical high risk for psychosis target simultaneously adolescents and young adults. International Journal of Technology Assessment in Health Care, 2019, 35, 408-409.	0.5	0
483	SSRIs and autism: interpreting an umbrella review – Authors' reply. Lancet Psychiatry,the, 2019, 6, 893-894.	7.4	0
484	Research Perspectives for Neuroimaging of Schizophrenia Spectrum Disorders. , 2019, , 303-325.		0
485	Neuroimaging and the Longitudinal Course of Schizophrenia. , 2019, , 183-218.		0
486	F94. EFFECTS OF OXYTOCIN ON NEUROCHEMICAL METABOLITES IN PSYCHOSIS RISK. Schizophrenia Bulletin, 2019, 45, S289-S290.	4.3	0

#	Article	IF	CITATIONS
487	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	0
488	T109. TRAVERSING THE TRANSDIAGNOSTIC GAP BETWEEN DEPRESSION, MANIA AND PSYCHOSIS WITH NATURAL LANGUAGE PROCESSING. Schizophrenia Bulletin, 2020, 46, S272-S273.	4.3	0
489	S154. TOBACCO SMOKING AND CLINICAL HIGH RISK: A SYSTEMATIC REVIEW AND META-ANALYSIS OF THE EVIDENCE. Schizophrenia Bulletin, 2020, 46, S94-S95.	4.3	0
490	T127. GENDER DIFFERENCES IN CLINICAL PRESENTATION AND ILLICIT SUBSTANCE USE DURING FIRST EPISODE PSYCHOSIS: AN ELECTRONIC CASE REGISTER NATURAL LANGUAGE PROCESSING ANALYSIS. Schizophrenia Bulletin, 2020, 46, S278-S279.	4.3	0
491	Acute Tryptophan Depletion and Suicidality. Journal of Psychophysiology, 2007, 21, 72-73.	0.7	0
492	Editorial. Current Pharmaceutical Design, 2012, , .	1.9	0
493	P.0178 Transition to psychosis in adolescents at clinical high risk for psychosis: a meta-analysis. European Neuropsychopharmacology, 2021, 53, S129-S130.	0.7	0